The five-year survival rate of mid-stage rectal cancer is 50-78%. The five-year survival rate of mid-stage rectal cancer, i.e., Stage II and Stage III rectal cancer, is 50-78% after systematic surgery, radiotherapy, chemotherapy and other comprehensive treatments. Of course, there will be some regional differences, but overall the prognosis is still relatively good. Meanwhile, some patients can combine with targeted drugs as well as traditional Chinese medicine treatment, immunotherapy and other methods to prolong the survival time. Complications of mid-term treatment of rectal cancer include intestinal perforation, anastomotic fistula, pulmonary atelectasis, lung infection, etc. There are also some complications of other treatments, including intestinal perforation and intestinal hemorrhage caused by radiotherapy, and severe gastrointestinal reaction and bone marrow suppression caused by chemotherapy. But overall, active treatment can greatly prolong the survival time and improve the quality of survival. Patients with mid-stage rectal cancer should follow up regularly and follow the doctor’s advice for scientific treatment in order to get the best prognosis.